Lathyrol, a potential multitarget anticancer drug may affect the cell cycle progression of RCC cells by influencing the signal transduction of the TGF-β/Smad pathway, or by directly influencing the expression of cyclin proteins and the cell cycle regulatory proteins CDK and CKI. This evidence concerns the gene PCNA and renal cell carcinoma.